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Abstract
Purpose This analysis compares salvage lymph node dissection (SLND) to salvage lymph node radiotherapy (SLNRT)
of 68Ga-PSMA PET-positive nodal recurrences after radical prostatectomy (RPE).
Methods A total of 67 SLNRT and 33 SLND consecutive patients with pelvic and/or para-aortic nodal recurrences after
RPE were retrospectively analyzed. Biochemical recurrence-free survival rates (bRFS; PSA <0.2ng/mL) were calculated
according to Kaplan–Meier and survival curves were compared using the log rank test. For multivariable analysis, binary
logistic regression analysis was performed (p< 0.05).
Results Median follow-up was 17 months (range, 6–53 months) in SLND patients and 31 months (range, 3–56 months)
in SLNRT patients (p= 0.027). SLNRT patients had significantly more tumours of pT3 and pT4 category (82% vs. 67%;
p= 0.006), pathologically involved lymph nodes (45% vs. 27%; p= 0.001) and positive surgical margins (54% vs. 12%;
p= 0.001) at time of RPE than SLND patients. PSA persistence after RPE was significantly more frequently observed
in the SLNRT cohort (73% vs. 27%; p= 0.001). There was no significant difference in the distribution of PET-positive
lymph nodes. Median PSA before SLND was higher than before SLNRT (3.07ng/ml vs. 1.3ng/ml; p= 0.393). The 2-year
bRFS was significantly higher in the SLNRT vs. the SLND cohort (92% vs. 30%; p= 0.001) with lower rates of distant
metastases (21% vs. 52%; p= 0.002) and secondary treatments (5% vs. 39%; p= 0.011) irrespective of ongoing androgen
deprivation therapy at last contact. In multivariable analysis, SLNRT was significantly associated with prolonged bRFS
(regression coefficient 1.436, hazard ratio 4.204, 95% CI 1.789–9.878; p= 0.001).
Conclusion Based on this retrospective study SLNRT might be the preferred treatment option for patients with nodal
recurrence after previous RPE.
Keywords Prostate cancer · PSMA PET/CT · Biochemical recurrence · Biochemical persistence · Radiotherapy · Salvage
lymph node dissection
Introduction
Up to 30% of patients with high-risk prostate cancer (PCa)
relapse after radical prostatectomy (RPE) with the majority
of patients having lymph node recurrences [1–3]. Manage-
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ment of lymph node recurrence after RPE is a challenging
clinical scenario, most times involving different specialists.
Salvage lymph node dissection (SLND) and salvage lymph
node radiotherapy (SLNRT) are the two possible treatment
options for metastasis-directed therapy (MDT) of node-pos-
itive PCa. Even though SLND and SLNRT are regularly
performed, there is sparse comparative data regarding ben-
eficial effects on survival outcomes.
In a recent systematic review on SLND, wide ranges
of 2- and 5-year biochemical recurrence-free survival rates
(bRFS) between 23 to 64% and 6 to 31%, respectively, have
been described. In addition, the 5-year overall survival was
about 84% [4]. However, it has to be stated that templates
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of SLND varied significantly between the currently avail-
able studies, as did adjuvant treatment, endpoints, and study
populations, and present evidence is mostly based on small
single-centre case series [4].
Likewise, few studies on SLNRT were identified in
a recent review: Patients with pelvic and/or extra-pelvic
nodes were either treated by stereotactic body radiother-
apy (SBRT) (55%) or elective nodal radiotherapy (ENRT)
(45%) to a lymph node region or the whole pelvic lym-
phatic pathways [5]. In patients treated with ENRT 3-year
progression-free survival ranged from 61.8 to 75% [6],
whereas in patients with SBRT to PET-positive lymph
nodes 3-year progression-free survival ranged between 26
and 33% [5]. This is strikingly comparable to outcome data
achieved by SLND, although one has to reconsider that the
majority of patients in the reported studies were staged at
best with choline positron emission tomography/computer
tomography (PET/CT) thus underestimating the true extent
of nodal recurrence.
Hereby, a significant benefit for 68gallium-prostate-spe-
cific membrane antigen PET/CT (68Ga-PSMA PET/CT) was
observed, and PSMA-PET/CT has since then evolved to-
wards the new imaging reference standard with a high de-
tection rate of lymph nodes in case of PSA persistence
or recurrence [7–11]. This might improve outcome by en-
abling a more extended lymphadenectomy or a higher dose
administration to PET-positive lymph nodes and at the same
time a more comprehensive ENRT.
Thus, this current analysis was restricted to patients with
PSMA PET-positive lymph node recurrences after RPE in
order to compare SLND to SLNRT at a tertiary care centre.
Materials andmethods
Patient population
Between February 2014 and December 2018, 100 con-
secutive patients underwent 68Ga-PSMA PET/CT prior to
SLNRT (67 patients) or SLND (33 patients) with evidence
of PET-positive pelvic and/or para-aortic lymph nodes af-
ter RPE. Patients who underwent previous adjuvant radio-
therapy of the pelvic lymphatic pathways or ADT prior to
SLNRT/SLND were excluded. Patients were subgrouped
according to the D’Amico criteria [12] incorporating tu-
mour-stage, PSA level and Gleason score (GS) (Table 1).
All patients provided written informed consent to undergo
68Ga-PSMA PET/CT. This retrospective analysis was per-
formed in compliance with the principles of the Declaration
of Helsinki and its subsequent amendments [13].
68Ga-PSMA labelling and PET/CT imaging
Radiolabelling of PSMA-HBED-CC was performed with
68Ga3+ from a 68Ge/68Ga generator system (GalliaPharm®,
Eckert & Ziegler AG, Berlin, Germany) using an automated
synthesis module (GRP, Scintomics GmbH, Munich, Ger-
many) and prepacked cassettes (ABX GmbH, Radeberg,
Germany) as described previously for a different PSMA
ligand by Weineisen et al. [14]. 68Ga-PSMA PET/CT imag-
ing was performed according to current guidelines [15] with
a Siemens Biograph 64 or GE Discovery 690 PET/CT cam-
era. Phantom studies based on the National Electrical Man-
ufacturers Association NU2-2001 standard were conducted
to allow valid pooling of the results, and standardized up-
take value (SUV) conversion factors were calculated [16].
68Ga-PSMA PET/CT scans were performed with a diag-
nostic CT scan (reference mAs, 200–240; 120kV) and ob-
tained with intravenous injection of iodine-containing con-
trast agent (Ultravist 300, Bayer Pharma AG, Berlin, Ger-
many; or Imeron 300, Bracco, Konstanz; 2.5mL/s; in portal
venous phase) around 60min after intravenous administra-
tion of 68Ga-PSMA. In absence of contraindications, 20mg
furosemide was injected almost simultaneously with 68Ga-
PSMA injection to lower tracer retention in the bladder.
PET images were reconstructed with an axial 168× 168 ma-
trix based on the TrueX algorithm (3 iterations, 21 subsets;
Biograph 64) or on the VUE Point FX algorithm (2 itera-
tions, 36 subsets; Discovery 690).
Image interpretation
PET/CT images were interpreted by a consensus read of
two nuclear medicine physicians and two radiologists in
the sense of a clinical report-based analysis. At least two of
the readers had more than 10 years PET/CT experience. The
location of each lesion was determined by CT. PET-posi-
tive lesions were visually identified by 68Ga-PSMA uptake
above background level and not associated with physiologic
uptake [15].
Radiotherapy
All patients received ENRT by intensity-modulated radio-
therapy (IMRT) or volumetric arc therapy (VMAT) and
image-guided radiotherapy techniques (IGRT, 2–5 times/
week). Radiotherapy dose regimens were normo- or slightly
hypofractionated and a boost to the PET-positive local re-
currences within prostatic fossa and lymph nodes was ap-
plied simultaneously. The prostatic fossa was treated with
a median of 66Gy (range, 60–67.20Gy) in single doses of
2Gy (range, 1.8–2.12Gy) and the elective lymphatic path-
ways with 50.4Gy (range, 45–52.28Gy) in single doses of
1.8Gy (range, 1.6–1.8Gy). PSMA PET-positive local re-
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Table 1 Patients’ characteristics
SLND SLNRT p-value
Patients n= 33 n= 67
Age (years) median (range) at time of LN dissection/RT 66 (52–83) 72 (47–83) 0.151
Initial PSA at RPE (ng/ml) median (range) 10.40 (2.01–262) 17.30 (3.99–190) 0.334
Gleason scorea 0.059
6–7 20 (61%) 28 (42%)
8–9 13 (39%) 39 (58%)
TNM at time of RPE
T-stage 0.006
T2 11 (33%) 12 (18%)
T3–4 22 (67%) 55 (82%)
N-stage 0.001
N0 17 (52%) 36 (54%)
N1 9 (27%) 30 (45%)
N x 7 (21%) 1 (1%)
Number of removed LN median (range) 11 (4–37) 14 (2–45)
Number of positive LN median (range) 0 (0–5) 0 (0–16)
M0 33 (100%) 67 (100%)
Positive surgical margins 4 (12%) 36 (54%) 0.001
D’Amico classification 0.967
Low 1 (3%) 2 (3%)
Intermediate 5 (15%) 5 (7%)
High 27 (82%) 60 (90%)
Postoperative PSA median (range) 0.30 (<0.03–10) 0.59 (<0.03–58) 0.642
PSA persistence/recurrence 0.001
Number of patients with PSA persistence 9 (27%) 49 (73%)
Number of patients with PSA recurrence 24 (73%) 18 (27%)
PSA at PET (ng/ml) median (range)
PSA persistence 1.75 (0.21–19.50) 1.60 (0.14–40.13) 0.391
PSA recurrence 1.70 (0.30–16.0) 0.67 (0.31–6.76) 0.342
PSMA PET/CT result 0.001
Lymph node positive only 33 (100%) 51 (76%)
Fossa and lymph node recurrence 0 (0%) 16 (24%)
Number of PET-positive lymph nodes (median; range) 1 (1–10) 2 (1–19) 0.392
Distribution of suspect lymph nodes 0.063
Pelvic 25 (76%) 54 (81%)
Retroperitoneal 4 (12%) 1 (1%)
Both 4 (12%) 12 (18%)
Time (months) between RPE and SLN dissection/RT start median (range) 0.941
All patients 9 (2–120) 6 (2–194)
PSA persistence 7 (2–84) 5 (2–86)
PSA recurrence 11 (2–120) 69 (9–194)
SLND salvage lymph node dissection, SLNRT salvage lymph node radiotherapy, PSA prostate specific antigen, RPE radical prostatectomy,
LN lymph node, RT radiotherapy
aData on Gleason score obtained from radical prostatectomy
currences within in the prostatic fossa were irradiated with
70.0Gy (range, 68–70Gy) and PSMA PET-positive lymph
nodes with 61.6Gy (range, 50.4–66Gy). Planning CT was
done in supine position with 3mm slice thickness. Patients
were advised to have a full bladder and empty rectum. Tar-
get delineation was performed according to the Radiation
Therapy Oncology Group (RTOG) atlas for salvage PCa
[17] and for lymphatic pathway delineation [18].
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Lymph node dissection
The standard SLND procedures at our department have
been described before [7, 19]. Briefly, an open approach
through an abdominal midline incision was used and stan-
dard extended SLND was performed based on specific
regions according to the most recent PSMA PET find-
ings. Dissected lymph nodes were classified based on the
respective anatomic region. Routinely, dissected lymph
nodes were immediately sent for histopathologic analy-
sis and evaluated according to standard protocols (serial
sectioning, 200μm slices).
Treatment application and follow-up
Treatment management following PSMA PET was docu-
mented for each patient. Follow-up time was defined as
the interval in months between SLND/SLNRT and the last
recorded PSA. Follow-up examination was first performed
6 weeks to 3 months after SLND/SLNRT and then every
6–12 months. Patients were regarded free of ADT influ-
ence after a minimum time-period of 5 months after last
application of ADT.
Statistical analysis
BRFS (PSA 0.2ng/ml) was defined as the primary study
endpoint. For statistical analysis, SPSS Statistics 25 (IBM,
New York, NY, USA) was used. Demographic data were
analysed using descriptive statistics and χ2 test. Time to
event data was calculated using the Kaplan–Meier method.
Differences between subgroups were compared using log
rank test with a p value of <0.05 considered statistically
significant. The χ2 test, Mann–Whitney U test and binary lo-
gistic regression were performed to determine the influence
of SLND vs. SLNRT, GS 6–7 vs. GS 8–9, tumour stage
T2 vs. T3–4, nodal stage N0/N x vs. N1, D’Amico stage
low/intermediate vs. high, PSA at salvage therapy, PSA
persistence vs. PSA recurrence and PET-positive pelvic vs.
pelvic and/or retroperitoneal lymph nodes on bRFS.
Results
Patients’ characteristics and PSMA PET results
Most patients (87/100; 87%) had a high-risk PCa at time of
RPE with no significant difference between the SLND and
SLNRT cohort. SLNRT patients had significantly more tu-
mours with locally advanced pT3 or pT4 disease (82% vs.
67%; p= 0.006) compared to the SLND cohort with sig-
nificantly more tumours of pT2 category (33% vs. 18%).
Furthermore, there were significantly more patients in the
SLNRT cohort with evidence of pathologically involved
lymph nodes (45% vs. 27%; p= 0.001) and positive sur-
gical margins (54% vs. 12%; p= 0.001) at time of RPE.
Overall, there were 58 patients with PSA persistence and
42 patients with PSA recurrence after RPE. SLNRT for
PET-positive lymph nodes was significantly more often ap-
plied in patients with PSA persistence (73%) than PSA re-
currence (27%). On the other hand, SLND was performed
significantly more often in patients with PSA recurrence
(73%) than PSA persistence (27%; p= 0.001) (Table 1).
Time between RPE and SLND/SLNRT was longer in pa-
tients with PSA recurrence than PSA persistence (6 vs.
44 months and 5 vs. 69 months). Patients with SLND had
only evidence of PET-positive lymph nodes (100%). Pa-
tients with SLNRT had PET-positive lymph nodes with
(24%) or without (76%) local recurrence within prostatic
fossa (p= 0.001). There was no significant difference in
the distribution of PET-positive lymph nodes between the
two cohorts: Only few patients had evidence of para-aor-
tic lymph nodes (24% in the SLND group and 19% in the
SLNRT group; p= 0.063).
Management of PET-positive lymph nodes and
toxicity
Median PSA prior SLND was higher than prior SLNRT
(3.07ng/ml vs. 1.3ng/ml; p= 0.393). Overall, a median of
8 (1–44) lymph nodes were removed at time of SLND.
Evidence of PCa was pathologically confirmed in a median
of 1 (0–16) lymph node. In total, there were 4 patients with
a Clavien Grade II (2× paralytic ileus, 2× lymphorrhea) and
2 patients with a Clavien Grade IIIa (2× pulmonary artery
embolism) complication (Table 2).
ADT was recommended to all patients with SLNRT due
to the evidence of PET-positive lymph nodes for 2 years
[20, 21]. Consequently, 59/67 (88%) patients were started
on ADT before initiation of SLNRT, 42/67 patients (63%)
discontinued after a median time of 7 (2–41) months due
to patients’ preferences. Median time between end of ADT
Table 2 Treatment characteristics of salvage lymph node dissection
cohort
SLND
Median PSA before LN dissection 3.07 (0.26–19.50)
Number of removed LN median
(range)
8 (1–44)






Clavien 4×Clavien II, 2× Clavien IIIa
SLND salvage lymph node dissection, LN lymph node
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Table 3 Treatment characteristics of radiotherapy cohort
SLNRT
Median PSA before LN RT 1.3 (0.10–40.13)
RT (Gy/median; range)
Former prostate 66 (60–67.2)
Lymphatic pathways 50.4 (45.0–52.28)
PET-positive local recurrence 70 (68–70)
PET-positive LN 61.6 (50.4–66)
RT technique
VMAT/IMRT & IGRT 67 (100%)
ADT with RT 59 (88%)




Ongoing ADT at last follow-up 17 (25%)
No ADT 8 (12%)
Toxicity Acute toxicity Late toxicity
n (%) n (%)
Grade 2 Grade 3 Grade 4 Grade 2 Grade 3 Grade 4
GU 19 (28%) 1 (2%) – 17 (25%) 1 (2%) –
GI 19 (28%) – – 1 (2%) – –
Other (erectile dysfunction) 6 (9%) 24 (36%)
SLNRT salvage lymph node radiotherapy, ADT androgen deprivation therapy, RT radiation therapy, VMAT volumetric modulated arc therapy,
IMRT intensity-modulated radiotherapy, IGRT image-guided radiotherapy, LN lymph node, GU genitourinary, GI gastrointestinal
and last follow-up was 27 months (range 0–48) in those
patients with discontinued ADT. In all, 8/67 (12%) pa-
tients refused ADT. Patients received radiotherapy treat-
ment as depicted above. Acute grade 2 gastrointestinal and
urogenital toxicity were each observed in 19/67 (28%) pa-
tients consisting primarily of diarrhoea and increased uri-
nary frequency. Acute grade 3 urogenital toxicity occurred
Fig. 1 Biochemical recur-
rence-free survival in patients
with salvage lymph node dissec-
tion (SLND) vs. salvage lymph
node radiotherapy (SLNRT) af-
ter metastasis-directed therapy
(MDT). mo months, HR hazard
ratio, 95% CI 95% confidence
interval
in 1/67 (2%) patients with evidence of urethral stenosis.
Late grade 2 toxicity was overall seen in 24/67 (36%)
patients with mainly signs of erectile dysfunction and in-
creased urinary frequency. Late grade 3 toxicity was present
in 25/67 (37%) patients with mainly erectile dysfunction
(36%) (Table 3).
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Median follow-up (months) 17 (6–53) 31 (3–56) 0.027
Posttreatment PSA (ng/ml) 0.47 (<0.03–9.61) 0.05 (<0.03–19.0) 0.003
PSA at last follow-up (ng/ml)
Median PSA (range) 2.50 (<0.03–68.0) 0.05 (<0.03–268) 0.025
PSA 0.1ng/ml 7 (21%) 46 (69%) 0.001
PSA 0.2ng/ml 10 (30%) 50 (75%) 0.001
PSA at last follow-up without ADT (ng/ml) n= 25 n= 42
Median PSA 1.21 (<0.03–13.0) 0.06 (<0.03–268) 0.02
PSA 0.1ng/ml 5 (20%) 32 (76%) 0.001
PSA 0.2ng/ml 7 (28%) 34 (81%) 0.001
Secondary treatment (ADT, RT, sx) 13 (39%) 10 (15%) 0.011
Clinical progress
Distant metastases 17 (52%) 14 (21%) 0.002
Death 0 3 0.549
Tumour-related 0 1 1.0
SLND salvage lymph node dissection, SLNRT salvage lymph node radiotherapy, ADT androgen deprivation therapy, PSA prostate specific antigen,
RT radiotherapy, sx surgery
Patient outcomes
Median follow-up was 17 months (range, 6–53 months) in
patients with SLND and 31 months (range, 3–56 months)
in patients with SLNRT (p= 0.027). Median posttreat-
ment PSA was significantly higher in patients with SLND
(0.47ng/ml, range <0.03–9.61ng/ml) than in patients with
SLNRT (0.05ng/ml, range <0.03–19ng/ml) (p= 0.003).
At last follow-up, median PSA was 2.50ng/ml (range
<0.03–68ng/ml) in patients with SLND and 0.05ng/ml
(range <0.03–268ng/ml) in patients with SLNRT (p= 0.025).
Overall, the 2-year bRFS was significantly higher in the
SLNRT cohort compared to the SLND cohort (92% vs.
30%; p= 0.001) irrespective of ongoing androgen depriva-
tion therapy at last contact (Fig. 1; Table 4). This resulted
in a significantly higher rate of distant metastases (52% vs.
21%; p= 0.002) and secondary treatments (39% vs. 15%;
p= 0.011) in patients with SLND. There was one tumour-
related death in the SLNRT group.
In multivariable analysis stratified for Gleason score at
RPE and PSA prior to PSMA PET/CT, SLND vs. SLNRT
Table 5 Multivariate analysis of factors associated with biochemical recurrence-free survival after salvage lymph node dissection/salvage lymph
node radiotherapy
Association with BRFS (<0.2ng/mL) Regression coefficient HR 95% CI p-Valuea
SLND vs. SLNRT 1.473 4.360 1.665–11.418 0.003
GS 6–7 vs. GS 8–9 1.063 0.345 0.135–0.883 0.027
PSA at salvage therapy [ng/ml] 0.064 1.066 0.991–1.147 0.087
aBinary logistic regression
SLND salvage lymph node dissection, SLNRT salvage lymph node radiotherapy, BRFS biochemical recurrence-free survival, GS Gleason Score,
PSA prostate specific antigen, HR hazard ratio, 95% CI 95% confidence interval
was significantly associated with bRFS (regression coef-
ficient 1.473, hazard ratio 4.360, 95% CI 1.665–11.418;
p= 0.003) (Table 5 and Supplemental Table 1).
Discussion
Management of lymph node recurrence after RPE is a chal-
lenging clinical scenario, and there is sparse comparative
data regarding the beneficial effects of SLND and SLNRT
on survival outcomes. Integration of existing evidence is
further hampered by differing patient characteristics, diag-
nostic modalities and therapy sequences [4]. Overall, it is
hypothesized that MDT to lymph node recurrences opti-
mizes the locoregional control, possibly limits the risk of
distant progression and thereby might improve cancer-spe-
cific survival, as has been described by mainly retrospective
data [22–26].
In the current study, bRFS of a contemporary patient co-
hort diagnosed with PSMA PET-positive nodal recurrence
of PCa after RPE is provided. To further homogenize the
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present patient cohort, none of the included patients had
ADT or adjuvant radiotherapy of the pelvic lymphatic path-
ways prior to SLND/SLNRT. In total, 100 patients (n= 33
SLND, n= 67 SLNRT) were included in the final analy-
sis, of whom all SLNRT patients were treated with ENRT
with simultaneous integrated boost (SIB) to the PET-pos-
itive lymph nodes. All surgically treated patients received
a standard extended SLND.
Regarding the patient characteristics, there were some
noticeable differences between the SLND and the SLNRT
subgroup. First, patients undergoing SLNRT had a sig-
nificantly higher proportion of nonorgan confined disease
as well as positive surgical margins at the time of RPE
compared to SLND patients. As expected, patients with
SLND were primarily patients with PSA recurrence (73%),
whereas the SLNRT cohort encompassed mostly patients
with biochemical persistence (73%). Finally, based on GS
score, there was a trend towards more high-risk patients
in the SLNRT patient cohort without reaching statistical
significance. Even though relevant differences between the
two patient subgroups cannot be overlooked, these patients
represent typical contemporary patient cohorts in tertiary
care centres. Hereby, the SLNRT cohort had overall worse
inherent features compared to the SLND cohort. Neverthe-
less, bRFS was significantly longer in the SLNRT cohort
compared to the SLND cohort irrespective of ongoing ADT
at the timing of last follow-up. Furthermore, patients of
the SLND cohort had a significantly higher rate of distant
metastases and need of secondary treatments.
Rischke et al. reported on a similar analysis of 93 patients
with exclusively nodal PCa relapse, but staged with choline
PET/CT who were either treated by SLND alone (46 pa-
tients) or SLND followed by RT (47 patients) to the regions
with proven lymph node metastases [27]: Additional RT led
to a significant delayed relapse within the treated region (5-
year relapse-free rate 70.7% vs. 26.3%), while time to next
relapse outside the treated region was almost equal (median
27 months vs. 29.6 months). Furthermore, patients treated
with both modalities had significantly lower rates of new re-
current pelvic lymph node metastases compared to patients
with surgery only (13% vs. 57.6%). Although, staged with
choline PET/CT, this study shows that with current imaging
possibilities patients seem to profit from a more extensive
therapeutic approach, like a more extended SLND or ENRT.
When one compares the present SLND cohort to groups
who studied explicitly patients staged with PSMA PET/CT,
one-year progression-free survival (PFS) ranged from 23 to
64%, with higher PFS found in patients with a radio-guided
SLND approach [4, 28–30] indicating that this might further
allow the dissection of affected lymph nodes that had not
been visualized beforehand on PET/CT. Overall, bRFS of
the present SLND cohort compares nicely to this range and
similar PFS ranges are known for SBRT cohorts [5].
This proportionally lower bRFS rate of the current pa-
tient cohort with SLND is comparable to a recent retrospec-
tive, multicentre analysis on SBRT vs. ENRT [31]: ENRT
was associated with significantly better 3-year metastasis-
free survival (77% vs. 68%) and significantly fewer indi-
viduals with local progression (9 vs. 50 patients) compared
to SBRT. Like non-extensive SLND, SBRT treats only the
PET-positive lymph nodes, whereas ENRT, as it was per-
formed in the current cohort, not only treats the PET-posi-
tive, affected nodes, but the whole lymphatic drainage, for
instance the entire pelvic lymphatic pathway as well as in
general the prostatic fossa especially in patients with lo-
cally advanced disease or positive surgical margins. Con-
gruent with the study of Rischke et al. [27], it was further
seen that patients following SBRT tend to relapse more of-
ten particularly in the pelvic lymph nodes. These findings
suggest again that the current imaging modalities are not
yet sensitive enough for a restricted node-based surgical or
radiotherapy approach [32].
Based on lymph node recurrences detected by choline
PET/CT following primary treatment for PCa, De Bruycker
et al. described the anatomic patterns of nodal oligorecur-
rent PCa in relation to different surgical (limited, standard,
superextended SLND) and radiotherapy templates. Corre-
spondingly, they found that with ENRT more patients were
theoretically fully covered (p< 0.02) and the total number
of covered lesions was higher (p< 0.001) when compared to
all types of SLND, except for superextended SLND, which
was comparable to ENRT. The authors concluded that lim-
ited or standard extended SLND might be insufficient as
a salvage treatment approach and ENRT or superextended
SLND should be preferred [33].
MDT to recurrent lymph node metastases is still contro-
versial and there is an ongoing debate whether it definitely
changes the disease outcome in the long-run or represents
just “PSA cosmetics” that comes at a cost of potential tox-
icity [34]. Clearly, its oncologic benefit is dependent on
patient selection. Fossati et al. evaluated 654 patients with
nodal recurrence after RPE who underwent SLND: At mul-
tivariable analysis, Gleason grade group 5, time from RPE
to PSA rising, ADT application at PSA rising after RPE,
retroperitoneal or three or more spots at PET/CT scan and
PSA level at SLND were significant predictors of clinical
recurrence after SLND [35].
Ongoing clinical trials, such as OLIGOPELVIS
(NCT02274779) that includes patients with 1–5 pelvic
nodal oligometastases who are treated with high-dose
radiotherapy and ADT for 6 months after prior radical
prostate treatment and the PEACE V trial (NCT03569241)
that randomizes patients with 3 oligorecurrent pelvic
lymph node metastases between MDT with 6 months
of ADT alone versus MDT with 6 months of ADT and
whole pelvis RT will further help to optimize the therapeu-
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tic approach in patients with oligometastatic lymph node
recurrences and are eagerly awaited.
Head-to-head comparisons of SLND to SLNRT, as was
performed in the current study, give an insight of what
might be the optimal treatment for patients with pelvic
lymph node recurrences but are not without limitations.
First, it has to be stated that the median follow-up was
shorter for the SLND cohort. This might result in an un-
derestimation of the real therapeutic effects of the two dif-
ferent treatment modalities. Second, this analysis was not
performed as a matched pair analysis due to the small pa-
tient number. Third, bRFS is not the optimal endpoint as
it is influenced by ADT use and 88% of SLNRT patients
received ADT concomitantly with RT. This might lead to
a more favourable bRFS in some patients, although the
majority (50/67; 75%) had no ADT at last follow-up and
42/59 (71%) of those with ADT concomitantly to RT had
discontinued it a median of 27 months (range 0–48 months)
before last follow-up. Fourth, none of SLND patients has
received postoperative adjuvant radiotherapy due to locally
advanced tumour or positive surgical margins posing an
undertreatment. This might partly explain the lower bRFS
in SLND patients and might lead to the conclusion that
SLND should primarily be undertaken in patients without
locally advanced disease or positive surgical margins when
adjuvant radiotherapy of prostatic fossa is withheld.
The aim of this comparative study was to explore the
possible treatment options for patients with PSMA PET-
positive, oligorecurrent nodal disease: With all its inherent
flaws of such an retrospective analysis, SLNRT seems to
be the preferred treatment option for patients with nodal
recurrences after previous radical prostatectomy especially
when undergoing a combination of SLNRT in the form of
an ENRT as it is performed in our institution and con-
comitant ADT with overall an acceptable toxicity profile.
The present results cannot be transferred to other surgi-
cal approaches like superextended SLND. Even though all
patients received PSMA PET-guided MDT [36], one can
state that with the current imaging modalities, also at the
time of PSMA PET/CT a more restricted surgical or radio-
therapy approach, like SBRT with the aim of less toxicity
cannot be safely performed yet. Despite its limitations, the
current study depicts real-world data from a tertiary-care
reference centre and might be hypotheses-generating for
future phase II trials.
Conclusions
In the current study, rare comparative data from a con-
temporary patient cohort diagnosed within the PSMA-
PET/CT era are provided. Significant differences regarding
patient characteristics were observed that must be consid-
ered for future trial design. Overall, in this retrospective
study a longer bRFS was observed in patients undergoing
PSMA PET-informed SLNRT as compared to SLND for
lymph node recurrent PCa. Findings need to be confirmed
in a prospective randomized trial.
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